Siegfried Holding AG engages in the life sciences business worldwide. More Details
No risks detected for SFZN from our risk checks.
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Siegfried Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SFZN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: SFZN's weekly volatility (4%) has been stable over the past year.
7 Day Return
CH Life Sciences
1 Year Return
CH Life Sciences
Return vs Industry: SFZN underperformed the Swiss Life Sciences industry which returned 62% over the past year.
Return vs Market: SFZN exceeded the Swiss Market which returned -0.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Siegfried Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StDo Fundamentals Have Any Role To Play In Driving Siegfried Holding AG's (VTX:SFZN) Stock Up Recently?
1 month ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Siegfried Holding AG's (VTX:SFZN) Shares?
5 months ago | Simply Wall StHow Many Siegfried Holding AG (VTX:SFZN) Shares Do Institutions Own?
Is Siegfried Holding undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SFZN (CHF618) is trading above our estimate of fair value (CHF526.76)
Significantly Below Fair Value: SFZN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SFZN's PE Ratio (59.6x) is in line with the XE Life Sciences industry average.
PE vs Market: SFZN is poor value based on its PE Ratio (59.6x) compared to the Swiss market (24.5x).
Price to Earnings Growth Ratio
PEG Ratio: SFZN is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: SFZN is good value based on its PB Ratio (3.7x) compared to the XE Life Sciences industry average (5.3x).
How is Siegfried Holding forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SFZN's forecast earnings growth (29% per year) is above the savings rate (-0.3%).
Earnings vs Market: SFZN's earnings (29% per year) are forecast to grow faster than the Swiss market (13% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SFZN's revenue (8.5% per year) is forecast to grow faster than the Swiss market (4.6% per year).
High Growth Revenue: SFZN's revenue (8.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SFZN's Return on Equity is forecast to be low in 3 years time (13%).
How has Siegfried Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SFZN has high quality earnings.
Growing Profit Margin: SFZN's current net profit margins (5.2%) are lower than last year (7.1%).
Past Earnings Growth Analysis
Earnings Trend: SFZN's earnings have grown by 10.2% per year over the past 5 years.
Accelerating Growth: SFZN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SFZN had negative earnings growth (-26%) over the past year, making it difficult to compare to the Life Sciences industry average (31.5%).
Return on Equity
High ROE: SFZN's Return on Equity (6.2%) is considered low.
How is Siegfried Holding's financial position?
Financial Position Analysis
Short Term Liabilities: SFZN's short term assets (CHF599.2M) exceed its short term liabilities (CHF168.5M).
Long Term Liabilities: SFZN's short term assets (CHF599.2M) exceed its long term liabilities (CHF307.4M).
Debt to Equity History and Analysis
Debt Level: SFZN is debt free.
Reducing Debt: SFZN has no debt compared to 5 years ago when its debt to equity ratio was 46.1%.
Debt Coverage: SFZN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SFZN has no debt, therefore coverage of interest payments is not a concern.
What is Siegfried Holding current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SFZN's dividend (0.45%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.62%).
High Dividend: SFZN's dividend (0.45%) is low compared to the top 25% of dividend payers in the Swiss market (3.79%).
Stability and Growth of Payments
Stable Dividend: SFZN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: SFZN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: SFZN is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SFZN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wolfgang Wienand (48 yo)
Dr. Wolfgang Wienand has been Chief Executive Officer at Siegfried Holding AG since January 01, 2019. Dr. Wienand has been President and Chief Executive Officer since January 2019 at Siegfried AG. Dr. Wien...
|Chief Executive Officer||2yrs||no data||0.40% |
|Chief Financial Officer||3.67yrs||no data||0.096% |
|Global Head of Technical Operations||4.17yrs||no data||0.24% |
|Chief Scientific Officer||1.75yrs||no data||0.0034% |
|Chief Compliance Officer||18yrs||no data||no data|
|General Counsel & Secretary||2yrs||no data||no data|
|Chief Communications Officer||21yrs||no data||no data|
|Global Head of Business Development||10.83yrs||no data||0.62% |
|Global Head of Human Resources||9.33yrs||no data||0.11% |
|Head of Quality Assurance & Qualified Person Siegfried Ltd||no data||no data||no data|
|Chief Strategy Officer||2yrs||no data||no data|
Experienced Management: SFZN's management team is considered experienced (3.9 years average tenure).
|Independent Non-Executive Director||8yrs||CHF205.15k||0.076% |
|Independent Chairman||7yrs||CHF430.56k||0.46% |
|Additional Director||0.75yr||no data||no data|
|Independent Non-Executive Director||7yrs||CHF195.51k||0.064% |
|Independent Non-Executive Director||9.67yrs||CHF215.73k||0.20% |
|Independent Non-Executive Director||5yrs||CHF195.51k||0.040% |
|Independent Director||5yrs||CHF226.30k||0.040% |
Experienced Board: SFZN's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Siegfried Holding AG's company bio, employee growth, exchange listings and data sources
- Name: Siegfried Holding AG
- Ticker: SFZN
- Exchange: SWX
- Founded: 1873
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF2.566b
- Shares outstanding: 4.15m
- Website: https://www.siegfried.ch
Number of Employees
- Siegfried Holding AG
- Untere BrUehlstrasse 4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SFZN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Jun 1994|
|0QQO||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Jun 1994|
|SQG||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Jun 1994|
|SGFE.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Jun 1994|
Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, includi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 18:16|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.